Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Business

Prima Biomed Commences "CANVAS" Clinical Trial in Europe


Print article Print article
© Marketwire 2013
2013-02-28 01:31:24 -

SYDNEY, AUSTRALIA -- (Marketwire) -- 02/27/13 -- Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima," the "Company") is pleased to announce that it has commenced recruitment of patients into the CANVAS (CANcer VAccine Study) trial in Europe. Prima has authorized several centers in Ukraine to start enrolling patients. CANVAS is a phase 2/3 study of CVac™ for the maintenance treatment of newly diagnosed, late-stage epithelial ovarian cancer patients who achieve remission after optimal debulking surgery and standard first line chemotherapy.





Prima has obtained the requisite ethics and regulatory approvals in multiple European countries, including Belarus, Belgium, Bulgaria, Germany, Lithuania, Latvia, Poland and Ukraine. The Company anticipates that the majority of CANVAS patients will be enrolled in Europe. The trial is currently open for recruitment at a number of centers in the United States and Australia.



Prima BioMed CEO Matthew Lehman said: "We are pleased to open enrollment for the CANVAS trial in Europe; we plan to progressively open sites across several European countries in the coming months. I would like to congratulate our clinical team and our manufacturing colleagues at the Fraunhofer Institute of Cell Therapy and Immunology for bringing us to this milestone."



Prima maintains updated information about the CANVAS trial and enrolling clinical centers on the U.S. National Institutes of Health clinical trial registry at www.clinicaltrials.gov : www.clinicaltrials.gov/ .



About CANVAS



The CANcer VAccine Study (CANVAS) is a multi-centre, randomized, and placebo-controlled study of CVac in mucin 1 positive, epithelial ovarian cancer patients who have undergone optimal surgery and achieve complete remission after first-line chemotherapy.



1000 patients will be recruited to CANVAS at over 100 hospitals throughout Australia, the USA, Europe, and Asia to have 800 evaluable study patients undergo dosing.



The study objectives are to ascertain if CVac, as compared to a placebo, is able to improve the time patients remain in remission before tumor progression (progression-free survival) and extend overall survival of patients. Safety parameters, quality of life impact, manufacturing quality, and additional laboratory assessments will also be investigated.



About Prima BioMed



Prima BioMed is a globally active biotechnology company. As a leader in personalized biotherapeutic products for cancer, Prima is dedicated to leveraging its current technology and expertise to develop innovative treatment options for patients and maximize value to shareholders. Prima's lead product is CVac™, an autologous dendritic cell product currently in clinical trials for ovarian cancer patients who are in remission.




For further information please contact:

USA Investor/Media:
Ms. Jessica Brown
Prima BioMed Ltd.
+1 (919) 710-9061
Email Contact : www2.marketwire.com/mw/emailprcntct?id=E465CA7FA7968A58

Australia Investor/Media:
Mr. James Moses
Mandate Corporate
+61 (0) 420 991 574
Email Contact : www2.marketwire.com/mw/emailprcntct?id=FE3799330F47BF67

Europe Investor/Media:
Mr. Axel Muhlhaus
edicto GmbH
+49 (0) 69 905505-52
Email Contact : www2.marketwire.com/mw/emailprcntct?id=B243D31E561DA98E



Press Information:




Contact Person:


Disclaimer: (c) 2014 Market Wire. All of the press releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Market Wire's, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com | BidVertiser